therapeutics News and Research

RSS

WEHI receives $2.5 million fund to develop personalized cancer treatments

With a $2.5 million fund received from the Medical Research Future Fund (MRFF), a new genomics project led by WEHI will develop precision medicine and customized cancer therapy for Australians.

From Walter and Eliza Hall Institute of Medical Research (WEHI) 27 Sep 2022

Researchers reveal key developmental difference between the brains of modern humans and Neanderthals

AZoLifesciences speaks to Dr. Anneline Pinson and Prof. Dr. Wieland B. Huttner from The Max Planck Institute of Molecular Cell Biology and Genetics about their latest research which found a greater neuron production in the frontal lobe during brain development in modern humans than Neanderthals, due to the change of a single amino acid in the protein TKTL1.

From The Max Planck Institute 20 Sep 2022

The deep relationship between Tob gene and common mental health conditions

The Tob gene is well known for its connection to cancer. Scientists have discovered that this gene also has a significant role in lowering depression, fear, and anxiety in a multidisciplinary study that blends molecular biology with neuroscience.

12 Sep 2022

MD Anderson and Virogin Biotech collaborate to advance the development of investigational oncolytic viruses, treatments

The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.

12 Sep 2022

Therapeutic mRNAs do not significantly impact translational fidelity

Synthetic mRNA therapeutics for the treatment and prevention of disease has attracted a lot of interest due to the exceptional efficacy of mRNA vaccinations against SARS-CoV-2.

30 Aug 2022

Mayo Clinic's strategic collaboration in biomanufacturing focuses on delivering novel biotherapeutics

Mayo Clinic today announced a strategic collaboration in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions.

17 Aug 2022

Mount Sinai and Regeneron Genetics Center launch a large-scale genome sequencing project

Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai have launched a new human genome sequencing research project called the Mount Sinai Million Health Discoveries Program with the Regeneron Genetics Center (RGC), part of the industry-leading, New York-based biotechnology company Regeneron.

12 Aug 2022

Mitochondrial DNA plays a crucial role in inflammation, study finds

Mitochondria are generally known as the powerhouse of the cell, however, growing research indicates that they may potentially be involved in inflammation.

8 Aug 2022

Scientists solve how RNA molecules reach their targets

Scientists claim that life does not come with an instruction manual, but this is not totally accurate. Each cell in our body follows the instructions provided by its DNA in the form of RNA molecules.

1 Aug 2022

Analyzing and acknowledging HIV protein may result in new treatments, study reveals

Researchers from Rutgers University and the Salk Institute defined the molecular structure of the HIV Pol polyprotein, a protein that helps the virus propagate and spread throughout the body, in an exploration that could lead to the formation of potential treatments for more than 40 million HIV patients globally.

From Rutgers University 11 Jul 2022

Challenges in Drug Discovery; Where are we now, and where are we going?

As part of our SLAS Europe 2022 coverage, we speak to Steve Rees, Vice-President of Discovery Biology at AstraZeneca, about the challenges currently faced by the drug discovery sector.

From Society for Laboratory Automation and Screening (SLAS) 8 Jul 2022

How can High-Content Screening accelerate Drug Discovery?

As part of our SLAS Europe 2022 coverage, we speak to Professor Jeremy Simpson from the University College Dublin about the role high-content screening can play in accelerating drug discovery.

From Society for Laboratory Automation and Screening (SLAS) 6 Jul 2022

Giving attention to beta cells instead of the immune system could be a chance to prevent type 1 diabetes

Research studying the autoimmune response, in which the immune system kills the insulin-producing pancreatic islet beta cells, is a common topic of type 1 diabetes research.

1 Jul 2022

Research highlights the new genetic variations and pediatric NAFLD severity

A multidisciplinary group of researchers at the University of California San Diego School of Medicine have advanced investigations into the genetic causes of NAFLD in children.

1 Jul 2022

Scientists discover proteins that may improve CAR-T cell therapy for solid tumor model

The potential of CAR T-cell therapy for the treatment of solid tumors was unlocked in a preclinical trial by researchers at St. Jude Children’s Research Hospital who discovered a molecular mechanism. The findings were released in the journal Nature.

27 Jun 2022

Integrating Science, Software, and Data to Accelerate Antibody Discovery

As part of our SLAS Europe 2022 coverage, we speak to Andrew LeBeau, Associate Vice President for Product Integrations at Dotmatics, about the importance of managing data within the life sciences and Dotmatic's Biology Solution for Antibody Discovery.

From Society for Laboratory Automation and Screening (SLAS) 16 Jun 2022

Novel nanoparticle therapeutic shows potential for treating human cancers

Researchers from Wake Forest University School of Medicine have discovered a possible new approach to treating solid tumors through the creation of a novel nanoparticle. Solid tumors are found in cancers such as breast, head and neck, and colon cancer.

15 Jun 2022

Spirea raises £2.4M ($3M) to develop antibody drug conjugates in cancer

Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours.

From Spirea 14 Jun 2022

Orbit Discovery awarded Innovate UK grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery

Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the UK’s innovation agency.

From Orbit Discovery 14 Jun 2022

Researchers utilize AI to reveal hitherto unknown 3D structures in rotavirus spike protein

The three types of rotavirus that cause gastroenteritis in individuals, known as groups A, B, and C, are the most well-known and afflict predominantly youngsters.

10 Jun 2022